Coincidental finding of Fabry's disease in a patient with IgA nephropathy

NDT Plus

Volumn 3, Issue 5, 2010, Pages 443-446

  Kakita, Tomoko ^a   Nagatoya, Katsuyuki ^a   Mori, Tatsuhiko ^a   Kobayashi, Masahisa ^b   Inoue, Toru ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fabry's disease; heterozygous female; IgA nephropathy

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE; ENALAPRIL;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FABRY DISEASE; FEMALE; GENETIC ANALYSIS; GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGLOBULIN A NEPHROPATHY; INCIDENTAL FINDING; KIDNEY BIOPSY; NEPHROSCLEROSIS; PRIORITY JOURNAL;

EID: 77956978054     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfq108     Document Type: Article

References (9)

1. Berger J, Hinglais N. Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris) 1968; 74: 694-695 in French
2. Desnick RJ, Joannou YA, Eng CM. α-Galactosidase a Deficiency: Fabry Disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The Metabolic and Molecular Bases of Inherited Disease. New York, USA: McGraw-Hill, 2001; 3733-3774
3. Yoshida A, Morozumi K, Takeda A et al. Fabry-like laminated myelin body associated with IgA nephropathy. Nippon Jinzo Gakkai Shi 1994; 36: 1303-1307 in Japanese
4. Kawamura O, Sakuraba H, Itoh K et al. Subclinical Fabrys disease occurring in the context of IgA nephropathy. Clin Nephrol 1997; 47: 71-75
5. Whybra C, Schwarting A, Kriegsmann J et al. IgA nephropathy in two adolescent sisters heterozygous for Fabry disease. Pediatr Nephrol 2006; 21: 1251-1256
6. Martinez P, Aggio M, Rozenfeld P. High incidence of autoantibodies in Fabry disease patients. J Inherit Metab Dis 2007; 30: 365-369
7. Sawada K, Mizoguchi K, Hishida A et al. Point mutation in the alphagalactosidase A gene of atypical Fabry disease with only nephropathy. Clin Nephrol 1996; 45: 289-294
8. Weidemann F, Niemann M, Breunig F et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009; 119: 524-529
9. Breunig F, Weidemann F, Strotmann J et al. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 2006; 69: 1216-1221